The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy
نویسندگان
چکیده
BACKGROUND Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with interferon beta (IFN beta) can develop neutralizing antibodies (NAbs) that reduce treatment efficacy. Several clinical studies explored the association of NAb+ status with increased disease activity. OBJECTIVE The aim of this study was to estimate the cost of RRMS patients who develop NAbs while treated with IFN beta by the Italian National Healthcare Service (NHS) and the Italian Society perspectives. METHODS The clinical data derived from a published observational study on 567 RRMS Italian patients treated with IFN beta. The management cost data derived from the published literature. Cost data were inflated to Euro 2014. RESULTS The annual direct cost to treat a patient was estimated in €15,428 in the NAb+ cohort and €14,317 in the NAb- cohort. The annual societal cost was estimated in €33,890 and €30,790 in NAb+ and NAb- patients, respectively. The cost increase related to the NAb+ status was €3,100 in the Italian societal perspective and €1,111 in the Italian NHS perspective. CONCLUSION The results of this economic evaluation suggest the presence of an association between NAb+ status and increased costs for the management of RRMS in Italy. Further pharmacoeconomic research will be needed to confirm this first result.
منابع مشابه
Acute Liver Dysfunction Associated With Interferon-Beta-1a (Avonex®) Use in A Young Female Patient with Relapsing-Remitting Multiple Sclerosis (RRMS)
Background: It has been reported that liver function alterations occur in 8–38% of patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon-beta in controlled clinical trials or in prospective but non-controlled studies. We report herein a case of symptomatic liver dysfunction associated with two-year-period of regular interferon-beta-1a (Avonex®) intramuscular inje...
متن کاملNeutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.
Biological drugs that have a protein or peptide structure provide new and highly eff e c t i v e therapies for a number of conditions and diseases, but their prolonged use in patients gives rise to new problems and questions, amongst them the possible occurrence of neutralizing antibodies (Nabs). We discuss some aspects of this particular problem in relation to interferon-beta therapy of multip...
متن کاملIncidence of antibodies in cerebrospinal fluid of patients with multiple sclerosis treated with interferon beta.
Dr. Andres M. Villa – División Neurología / Hospital General de Agudos “José María Ramos Mejía” / School of Medicine / Buenos Aires University Urquiza 609 (1221) Buenos Aires, Argentina. E-mail: [email protected] Interferon beta (IFNβ) is used in the treatment of multiple sclerosis (MS) because it can reduce relapse rate and lesion formation on MRI and can slow progression of the disease....
متن کاملAnti-interferon antibodies in multiple sclerosis. Molecular basis and their impact on clinical efficacy.
Low levels of naturally-occurring, high-affinity antibodies directed against cytokines can be found in the circulation of individuals who have never been exposed to exogenously-supplied cytokines. These antibodies are thought to play a regulatory role in the intensity and duration of immune response. Interferon (IFN) beta has been shown to attenuate both relapsing-remitting multiple sclerosis (...
متن کاملClinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.
OBJECTIVES To confirm that neutralizing antibodies (NAb) to interferon beta can persist after therapy withdrawal and to evaluate whether persisting NAb are associated with a worse clinical disease course in multiple sclerosis (MS). DESIGN Retrospective study. SETTING Tertiary referral center in The Netherlands. PATIENTS A total of 71 patients with relapsing-remitting multiple sclerosis tr...
متن کامل